Результаты поиска

ESICM LIVES 2016: part three : Milan, Italy. 1–5 October 2016

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation.

Use of haematopoietic cell transplantation (HCT) in the treatment of haematologic and neoplastic diseases may lead to life-threatening complications that cause substantial morbidity and mortality if untreated. In addition to patient- and disease-related factors, toxicity associated with HCT puts patients at risk for complications that share a similar pathophysiology involving endothelial cells (ECs). Normally, the endothelium plays a role in maintaining homeostasis, including regulation of coagulation, vascular tone, permeability and inflammatory processes. When activated, ECs acquire cellular

How the COVID-19 Pandemic Reshaped the Management of Leukemia and Affected Patient Outcomes.

Opinion statementThe coronavirus disease-19 (COVID-19) pandemic has posed numerous challenges to the global healthcare system. Of particular gravity is adult and pediatric patients with hematologic malignancies who are among the most vulnerable groups of patients at risk of severe COVID-19 outcomes. In the early phases of the pandemic, several treatment modifications were proposed for patients with leukemia. Largely speaking, these were adopting less-intense therapies and more utilization of the outpatient setting. Over time, our understanding and management have become more nuanced. Furthermo

The Impact of Iron on Cancer-Related Immune Functions in Oncology: Molecular Mechanisms and Clinical Evidence.

Iron metabolism plays a dual role in cancer, serving as an essential nutrient for cellular functions and a potential catalyst for tumor growth and immune evasion. Here, we cover the complex interplay between iron levels within the serum or in the microenvironment and cancer therapy, focusing on how iron deficiency and overload can impact immune function, tumor progression, and treatment efficacy. On the one hand, we highlight iron deficiency as a factor of primary immune responses and its adverse effects on anti-cancer immunotherapy efficacy. On the other hand, we also stress the impact of iro

Селинксор в сочетании с помалидомидом и дексаметазоном для лечения первичной плазменной лейкемии с 1q21+ аномалией: отчет о деле.

RATALE: Первичная плазменная лейкемия клеток представляет собой редкое и крайне агрессивное нарушение системы крови с быстрым распространением заболеваний и высоким коэффициентом ранней смертности. В настоящее время не существует признанного терапевтического режима, что приводит к принятию стратегий, обычно используемых в отношении множественной миэломы, которая, однако, демонстрирует ограниченную эффективность. Селинксор считается эффективным средством лечения рецидива/рефрактора множественной миеломы, однако в настоящее время нет сообщений о его применении в первичном лейкемии клеток плазмы.

Совпадение в полном тексте источника
… Concurrent treatments included anti-infection therapy, correction of electrolyte imbalances, liver, and kidney protection, correction of hypoalbuminemia, parenteral nutrition, and blood component transfusions. …

Abstracts of the 36th Annual Meeting of the Society of General Internal Medicine. April 24-27, 2013. Denver, Colorado, USA.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Минимальная информация для исследований внеклеточной везиклетки (MISEV2023): от базовых до передовых подходов.

Внеклеточные везиклолы (ЭМ) с помощью своего сложного груза могут отражать состояние клетки их происхождения и изменять функции и фенотипы других ячеек. Эти особенности свидетельствуют о значительном биомаркировании и терапевтическом потенциале и вызывают широкий интерес, о чем свидетельствует постоянное увеличение числа научных публикаций об ЭМ за год. Значительные успехи были достигнуты в области ЭВМ, а также в понимании и применении биологии ЭМ. Вместе с тем сохраняются препятствия на пути реализации потенциала ЭМ в различных областях - от базовой биологии до клинического применения - в свя

2020 ACVIM Forum On Demand Research Abstract Program.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Safety, Precautions, and Modalities in Cancer Rehabilitation: an Updated Review.

Purpose of reviewProviding rehabilitation to patients with cancer can be challenging due to the medical complexity associated with the illness and its treatments. This article provides the reader with a summary of frequently encountered medical conditions in the cancer population and associated safety considerations and precautions. An update on treatment modalities commonly used for symptom management is also presented.Recent findingsCancer and cancer treatments can cause changes in multiple organ systems. Special considerations and precautions are necessary to provide safe and effective reha

Preclinical efficacy of tasquinimod in myelodysplastic neoplasms: Restoring erythropoiesis and mitigating bone loss.

Myelodysplastic neoplasms (MDSs) are clonal disorders characterized by ineffective hematopoiesis, dysplasia, and a risk of transformation into acute myeloid leukemia. MDS is also associated with a higher incidence of osteoporosis, suggesting a complex interplay between hematopoiesis, the bone marrow (BM) microenvironment, and bone homeostasis. Targeting inflammation has emerged as a promising therapeutic strategy, particularly in lower risk MDS. Tasquinimod (TASQ) is a small-molecule inhibitor of the inflammatory alarmin S100A9, blocking its interaction with TLR4 and RAGE receptors. We investi

Exercise and the immune system: taking steps to improve responses to cancer immunotherapy.

The remarkable success of cancer immunotherapies has provided new hope to cancer patients. Unfortunately, a significant proportion of patients remain unable to respond to immunotherapy or maintain durable clinical responses. The lack of objective responses likely results from profound immune dysfunction often observed in patients with cancer. There is substantial evidence that exercise and physical activity can reduce incidence and improve outcomes in cancer patients. As the immune system is highly responsive to exercise, one potential avenue to improve immune function is through exercise and

Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery.

Natural Killer (NK) cells are exciting candidates for cancer immunotherapy with potent innate cytotoxicity and distinct advantages over T cells for Chimeric Antigen Receptor (CAR) therapy. Concerns regarding the safety, cost, and scalability of viral vectors has ignited research into non-viral alternatives for gene delivery. This review comprehensively analyses recent advancements and challenges with non-viral genetic modification of NK cells for allogeneic CAR-NK therapies. Non-viral alternatives including electroporation and multifunctional nanoparticles are interrogated with respect to CAR

Oral Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Recognition and management of early complications in CAR-T cell therapy and virus-specific T-lymphocyte therapy: a practical clinical reference.

BACKGROUND: Cellular immunotherapies-including chimeric antigen receptor T-cell (CAR-T) therapies and adoptive transfer of virus-specific T lymphocytes (VSTs) - have transformed the treatment of refractory hematological malignancies and post-transplant infectious complications. Eight products are currently authorized by the European Medicines Agency, encompassing seven autologous CAR-T products targeting CD19 or BCMA and tabelecleucel (Ebvallo), the first approved allogeneic off-the-shelf EBV-specific T-cell product for EBV-positive post-transplant lymphoproliferative disease. Despite their cl

Monoclonal Gammopathy of Undetermined Significance Diagnosed by Persistent Anemia Following Living Kidney Transplantation: A Case Report.

The prevalence of monoclonal gammopathy of undetermined significance increases with age, and there may be undiagnosed patients among kidney transplant recipients. A 69-year-old woman underwent ABO-incompatible living-donor kidney transplantation. Her renal function improved immediately postoperatively. Her hemoglobin level gradually increased to 10.5 g/dL at 3 months postoperatively but gradually decreased to 7.3 g/dL at 9 months postoperatively. We administered an erythropoiesis-stimulating agent and consulted the Department of Hematology. Bone marrow aspiration revealed that the pathological

Воздействие витамина D на герпесвирусные инфекции.

Помимо своей классической роли в регулировании метаболизма кальция и фосфата, витамин D также оказывает значительное влияние на модуляцию иммунитета. Витамин D регулирует иммунную реакцию, переходя от воспламенительного состояния к более толерогенному one путем увеличения выброса антивоспалительных цитокинов при одновременном ослаблении регулирования проинфламаторных цитокинов. Таким образом, низкий уровень витамина D связан с повышенным риском возникновения аутоиммунных заболеваний, таких, как множественный склероз и тип 1 диабет. Кроме того, этот прохормон также способствует высвобождению хо

Association between risk of malnutrition defined by patient-generated subjective global assessment and adverse outcomes in patients with cancer: a systematic review and meta-analysis.

ObjectiveTo assess the association between the risk of malnutrition, as estimated by the Patient-Generated Subjective Global Assessment (PG-SGA) numerical scores, and adverse outcomes in oncology patients.DesignSystematic review and meta-analysis.SettingsA comprehensive search was conducted in PubMed, Web of Science, Embase, CKNI, VIP, Sinomed and Wanfang databases. Studies that examined the association between the risk of malnutrition, as estimated by the PG-SGA numerical scores, and overall survival (OS) or postoperative complications in oncology patients were included. Patients were classif

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable

The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Session (P001-P706).

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.